CEL-SCI's Insider Warrant Buy; May Underscore Value of Shares

Print E-mail
By David Ibrahim   
Tuesday, 08 April 2014 03:41

icon_insiderbuysChief Executive Officer, Geert Kersten of Phase III drug developer CEL-SCI (AMEX:CVM)  made a notable insider purchase of 170,000 Series S Warrants confirmed by a Form 4 filing reported on Monday with the Securities and Exchange Commission.

Read more...
 

3 Small Cap Biotechs With Near-Term Catalysts

Print E-mail
By Scott Matusow   
Thursday, 06 March 2014 10:17

Synthetic Biologics (SYN) expects to present top-line data from its Trimesta/Copaxone combo Phase II multi-center clinical trial involving 164 women for the treatment of relapsing-remitting multiple sclerosis (MS) in women.

Read more...
 

Xenoport Gaining Momentum, Could It Be The Next Small Cap Biotech Flyer

Print E-mail
By Scott Matusow   
Tuesday, 25 February 2014 08:16

Xenoport (XNPT) focuses on developing and commercializing a portfolio of internally discovered product candidates for the treatment of neurological disorders.

Read more...
 

Synthetic Biologics Under The Radar With Upcoming Multiple Sclerosis Data Catalyst

Print E-mail
By Scott Matusow   
Thursday, 20 February 2014 08:29

Similar to how a blue-chip company might have an increase in stock price before an earnings call, small-cap developmental biotechs often increase in price before important clinical data releases, Advisory Committee Meetings (ADCOM), and U.S. Food and Drug Administration (FDA) drug approvals.

Read more...
 

Significant Upcoming Catalysts For These Biotechs Should Provide Opportunity

Print E-mail
By Scott Matusow   
Friday, 14 February 2014 08:48

This week we want to highlight several biotechs with catalysts coming up in the near future. These price driving catalysts may include FDA approval decisions, FDA Advisory Committee (ADCOM) recommendations, product launches, and clinical data releases.

Read more...
 

Here’s one to avoid – Oramed Pharmaceuticals

Print E-mail
By Brian Wilson-Lead Contributor   
Tuesday, 11 February 2014 12:50
Oramed (ORMP) is another diabetes company that is looking to enter the insulin market. This time, the twist is that the insulin comes in an oral form (a capsule) with special proteins that allow for proper absorption.
Read more...
 

This Biotech Is Flying Under The Radar With Catalyst Upcoming

Print E-mail
By Scott Matusow   
Tuesday, 11 February 2014 09:54
Today we are going to take a look at a developmental biotech which well-known biotech institutional investor firm Baker Brothers LLC has a substantial position in.
Read more...
 

Why La Jolla Pharma has very favorable Risk/Reward

Print E-mail
By Brian Wilson - Lead Contributor   
Tuesday, 04 February 2014 10:01
It's becoming more and more difficult to find biotechnology stocks that are attractively valued these days. The NASDAQ Biotechnology index (NBI), the best "barometer" for this sector, is up 253% in the last 5 years.
Read more...
 

A Top-Down View on Multibillion Dollar Colorectal Cancer Diagnostics Market

Print E-mail
By Brian Wilson-Lead Contributor   
Monday, 27 January 2014 00:13
Routine colorectal cancer screening is something that tens of millions in the United States go through every few years.
Read more...
 

ThermoGenesis Merging with TotiRx – Heating Up Cell Therapy M&A

Print E-mail
By Brian Wilson-Lead Contributor   
Tuesday, 21 January 2014 02:01
In a previous article, I mentioned that stem cell companies are coming back in a big way.
Read more...
 
<< Start < Prev 1 3 4 5 6 7 8 9 10 > End >>

Page 1 of 43
BioMedReports Galectin Announces First Patient Dosed in Phase 1 Trial of GR-MD-02; Targeted Medical Pharma Completes Middle ... http://t.co/ia50TaWnPa
BioMedReports Key milestone for brown fat research with a ground-breaking MRI scan http://t.co/MQTeFGrMOj
BioMedReports Baxter Announces Primary Efficacy Endpoint for Phase 3 Trial of BAX 11; Cleveland Biolabs Successfuly Close of... http://t.co/vhI1HwOLoB